TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01873131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topical timolol maleate
Description: Timolol maleate 0.5% ophthalmic solution will be used. The dose will be 1 drop per square centimeter of hemangioma, rubbed into the area by the parent/guardian twice daily. The intent is to cover the entire lesion without excess of medication. Therefore, the dose can be lowered from 1 drop/cm2 at the discretion of the investigators, but not increased. This dose should not have significant systemic side effects given that the normal systemic intravenous dose for propanolol is 2mg/kg/day and there would be much less systemic absorption if the solution is applied topically. It is well established that the stratum corneum greatly slows the transport of timolol.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulsed dye laser
Description: A 595-nm PDL (V-beam Perfecta, Candela Corp, Wayland, MA, USA) with a dynamic cooling device (DCD) will be utilized for all treatments. This device is cleared by the FDA for clinical treatment of vascular lesions. Protective eyewear for patient and all participants in the treatment room will be provided. A spot size of 7 or 10 mm will be used with an average fluence (energy delivered per unit area, in J/cm2) of 9 J/cm2 (range 8-10.0 J/cm2). Fluence will vary according to patient and hemangioma characteristics, including age, skin type, location, lesion thickness and response to treatment. A 30-50 ms cryogen spray cooling (CSC) duration will precede the laser pulse duration of 0.4 ms.
Study: NCT02623530

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational intervention
Description: Control Group: An educational intervention focusing on first aid for the development of skills and dispositions of critical thinking. For this group will be taught the contents of first aid through the Methodology of PBL without the support MEAPC.~Experimental Group: An educational intervention focusing on first aid for the development of skills and dispositions of critical thinking. For this group will be taught the contents of first aid through Methodology PBL, supported by the MEAPC.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational intervention
Description: Control Group: An educational intervention focusing on first aid for the development of skills and dispositions of critical thinking. For this group will be taught the contents of first aid through the Methodology of PBL without the support MEAPC.~Experimental Group: An educational intervention focusing on first aid for the development of skills and dispositions of critical thinking. For this group will be taught the contents of first aid through Methodology PBL, supported by the MEAPC.
Study: NCT04027777

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aktiia.product-P0
Description: The optical signals at the wrist are recorded non-invasively by means of the Aktiia.product-P0 investigational device. The BP measurements are further determined from these optical signals and are compared to the reference double auscultation BP readings. A reference-control volume clamp BP reading is recorded simultaneously.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aktiia.product-P0
Description: The optical signals at the wrist are recorded non-invasively by means of the Aktiia.product-P0 investigational device. The BP measurements are further determined from these optical signals and are compared to the reference double auscultation BP readings. A reference-control volume clamp BP reading is recorded simultaneously.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aktiia.product-P0
Description: The optical signals at the wrist are recorded non-invasively by means of the Aktiia.product-P0 investigational device. The BP measurements are further determined from these optical signals and are compared to the reference double auscultation BP readings. A reference-control volume clamp BP reading is recorded simultaneously.
Study: NCT04382599

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text warning with square background
Description: The warning message is in white text on a black square background
Study: NCT01142739

Intervention type: OTHER
Intervention: Clinical variables
Description: Eye movement recordings : non-invasive infra-red camera oculometry (EyeBrain) before and after (only parkinson's disease group) levodopa(10 to 15 minute/recording)
Study: NCT02625493

Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaire containing a Best-worst Scaling scenario
Study: NCT04382599

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text warning with square background
Description: The warning message is in white text on a black square background

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Text warning with square background
Description: The warning message is in white text on a black square background

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text warning with square background
Description: The warning message is in white text on a black square background
Study: NCT02892981

Intervention type: OTHER
Group type: OTHER
Intervention: cardiopulmonary exercise test,hypoxia and hypercapnia test
Description: class I and IV Pulmonary hypertension patients in stable haemodynamic status and optimized medical therapy underwent cardiopulmonary test and hypoxia and hypercapnia tests to evaluate the chemoreceptor sensitivity
Study: NCT03921411

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nemolizumab
Description: Participants received subcutaneous (SC) injection of 30 milligram (mg) of Nemolizumab every 4 weeks (Q4W) over a 16-week treatment period, with a loading dose of 60 mg on Day 1.
Study: NCT03792685

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normo-carbohydrate meal intake
Description: Subjects are going to receive the normo-carbohydrate meal.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normo-carbohydrate meal intake
Description: Subjects are going to receive the normo-carbohydrate meal.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normo-carbohydrate meal intake
Description: Subjects are going to receive the normo-carbohydrate meal.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-carbohydrate meal intake
Description: Subjects are going to receive the high-carbohydrate meal.
Study: NCT00955929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo QHS and sildenafil and questionnaires
Description: Pts will be offered sildenafil 100 mg to be used before intercourse on an as-required basis. They will be given six 100 mg doses, per month, for a 12-month duration. Each patient in this group will use a placebo pill (blinded) each night, except on a nights that 100mg is taken for the purpose of sexual relations. Patients will be evaluated in the clinic and will complete the questionnaires at baseline (pre-treatment evaluation), 3, 6, 9, 12, 18 and 24 months after the operation. At 12 months postoperatively, all patients will stop treatment. Visits 3, 6, 9, 12, 18, and 24 months will have ±2 week window.
Study: NCT03792685

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-carbohydrate meal intake
Description: Subjects are going to receive the high-carbohydrate meal.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-carbohydrate meal intake
Description: Subjects are going to receive the high-carbohydrate meal.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-fat meal intake
Description: Subjects are going to receive the high-fat meal.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-fat meal intake
Description: Subjects are going to receive the high-fat meal.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-fat meal intake
Description: Subjects are going to receive the high-fat meal.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-protein meal intake
Description: Subjects are going to receive the high-protein meal.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-protein meal intake
Description: Subjects are going to receive the high-protein meal.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-protein meal intake
Description: Subjects are going to receive the high-protein meal.
Study: NCT04181918

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AOT
Description: During action observation, participants observe different daily actions (e.g. reading a newspaper; drinking an espresso) divided into up to four motor segments.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MI
Description: During motor imagery, participants imagine themselves performing the same daily actions as in AOT in the absence of motor output
Study: NCT02102139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DXM + Propofol
Description: After induction as mentioned at 'arm description', the effect-site propofol concentration was fixed at 5.0 μg mL-1 at the time of diluted epinephrine injection and was unchanged during the entire hydrodissection period in all patients.~The first patients received effect-site concentrations of remifentanil of 4 ng mL -1, respectively. The EC50 of remifentanil for stable hydrodissection was determined by a modification of Dixon's up-and-down method.If the response was success (SBP during the entire hydrodissection period being ±20% from baseline), the next target concentration of remifentanil was decreased by a step of 0.5 ng mL -1. If the response was fail(SBP \> ±20% from baseline), the target concentration was increased by 0.5 ng mL-1.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline + Propofol
Description: All procedure would be same in DXM+Propofol group except saline loading rather than DXM loading before induction.
Study: NCT03560713

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation (FES)
Description: Participants will perform 12 weeks of FES (Neurodyn High Volt, IBRAMED, São Paulo/SP, Brasil), three times a week, frequency 25Hz, pulse rate of 200μs, ON:OFF 5:5, individual maximum tolerated intensity; minimum at strong but comfortable visible muscle contraction (without causing undue pain or discomfort to the participant). during 30 minutes nd receive aerobic exercise training and resistance exercises for upper limbs and lower limbs.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Functional Electrical Stimulation (FES) sham
Description: Participants will perform 12 weeks of Functional Electrical Stimulation (FES) sham (Neurodyn High Volt, IBRAMED, São Paulo/SP, Brasil), three times a week, frequency 5Hz, pulse rate of 200μs, ON:OFF 5:5, without muscle contraction during 30 minutes nd receive aerobic exercise training and resistance exercises for upper limbs and lower limbs.
Study: NCT04139785

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moodbuster
Description: Moodbuster intervention comprises three elements: (1) a web-based interface providing the patients access to CBT therapies, (2) a web-based portal for the trial co-ordinator and researchers, where they can view participation, amend modules and send login codes, (3) a mobile phone component which enables daily EMA monitoring of mood state, cognitions, activities, social interaction, and sleep.~The mobile application will be used to capture EMA data.
Study: NCT04720859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 MG Oral Tablet
Description: Patients diagnosed with PHH following bariatric surgery by 100g glucose OGTT were prescribed 300mg canagliflozin during two weeks. 100g glucose OGTT response was evaluated after canagliflozin treatment.
Study: NCT01485601

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MT10109
Description: Single dose intramuscular injection MT10109 vs Botox®

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MT10109
Description: Single dose intramuscular injection MT10109 vs Botox®
Study: NCT00955929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil and questionnaire
Description: Patients will be instructed to take sildenafil 50 mg QHS (blinded) except on nights that they are interested in sexual relations, they will then be instructed to use sildenafil 100mgs (open-label) and skip the 50mg dose. Sildenafil treatment will start within 24-48 hours post-surgery. Patients will be evaluated in the clinic and will complete the questionnaires at baseline (pre-treatment evaluation), 3, 6, 9, 12, 18 and 24 months after the operation. At 12 months postoperatively, all patients will stop treatment. Visits 3, 6, 9, 12, 18, and 24 months will have ±2 week window

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimix combination (Papavarine 30mg/mL Phentholamine 1mg/mL Prostaglandin E1 10 mcg/mmL) and questionnaires
Description: Intracavernous injections of a trimix combination (Papaverine 30mg/mL Phentholamine 1mg/mL Prostaglandin E1 10 mcg/mL) will be injected three times a week, and sildenafil 50mg taken on the other four (non-injection) nights. Injection therapy can be used for the purpose of sexual relations. Patients will be evaluated in the clinic and will complete the questionnaires at baseline (pre-treatment evaluation), 3, 6, 9, 12, 18 and 24 months after the operation. At 12 months postoperatively, all patients will stop treatment. Visits 3, 6, 9, 12, 18, and 24 months will have ±2 week window.
Study: NCT04382599

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text warning with square background
Description: The warning message is in white text on a black square background

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text warning with octagon background
Description: The warning message is in white text on a black octagon background

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text warning with octagon background
Description: The warning message is in white text on a black octagon background

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text warning with octagon background
Description: The warning message is in white text on a black octagon background
Study: NCT02390583

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT treatment of internet dependence
Description: CBT treatment of internet dependence

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT treatment of internet dependence
Description: CBT treatment of internet dependence

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT treatment of sleep disorders
Description: CBT treatment of sleep disorders
Study: NCT04898231

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab
Description: Infliximab will be administered as a single IV dose of 10 mg/kg over 2 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anakinra
Description: Anakinra will be administered at a dose of 8 mg/kg/day IV or SQ with 100 mg every 6 hours as the max dose. This is discontinued with a taper during the hospitalization over 2-4 days once a patient is stable with significantly improved clinical course and laboratory profile.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Methylprednisilone (steroids) will be administered as 2 mg/kg IV or orally divided every 12 hours. At the time of hospital discharge the patient will be given a steroid taper that will take at least 3 weeks to complete.
Study: NCT03603795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: Eltrombopag concomitant with induction chemotherapy in patient with AML

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo concomitant with induction chemotherapy patients with AML
Study: NCT01844635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thymoglobulin
Study: NCT01427296

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene glycol
Description: HalfLytely and Bisacodyl Tablet Bowel Prep Kit, administered as 1 bisacodyl tablet followed by HalfLytely oral solution in a total liquid volume of approximately 2 L

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral sodium phosphate solution
Description: OsmoPrep tablets (48 g), administered as 32 total tablets in a total liquid volume of approximately 2 L
Study: NCT02665975

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT-based internet-intervention for tinnitus
Description: Tinnitus e-learning programme

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Face-to-face clinical tinnitus care
Description: Hospital tinnitus counselling
Study: NCT00958880

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Group Cognitive Behavioral Therapy
Description: 5 weeks of group CBT for Social Anxiety. The aim of CBT is to help participants become more comfortable with social situations~One arm will receive placebo augmented Group Cognitive Behavioral Therapy and the other will receive yohimbine hydrochloride augmented cognitive behavioral therapy.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Cognitive Behavioral Therapy
Description: 5 weeks of group CBT for Social Anxiety. The aim of CBT is to help participants become more comfortable with social situations~One arm will receive placebo augmented Group Cognitive Behavioral Therapy and the other will receive yohimbine hydrochloride augmented cognitive behavioral therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yohimbine Hydrochloride
Description: Participants in the Yohimbine augmented arm will receive 4 doses of Yohimbine Hydrochloride before 4 of the 5 group cognitive behavioral therapy sessions.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill
Description: Participants in the placebo (sugar pill) augmented arm will receive 4 doses of a sugar pill before 4 of the 5 group cognitive behavioral therapy sessions.
Study: NCT01342562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: spinal anesthesia
Description: 0.4% bupivacaine(normal saline 0.3ml with dexmedetomidine 3 mcg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: spinal anesthesia
Description: 0.4% bupivacaine(normal saline 0.3 ml with 0.5% bupivacaine 1.2 ml)
Study: NCT02451566

Intervention type: DEVICE
Intervention: Ovation Prime Abdominal Stent Graft System

Intervention type: DEVICE
Intervention: Ovation Prime Abdominal Stent Graft System

Intervention type: DEVICE
Intervention: Ovation Prime Abdominal Stent Graft System
Study: NCT01544972

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral paracetamol
Description: Patients will receive oral paracetamol 15 mg/kg per dose every 6 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral ibuprofen
Description: Patients will receive oral ibuprofen at an initial dose of 10 mg/kg, followed by 5 mg/kg at 24 and 48 h.
Study: NCT04380207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QPX7728
Description: antibiotic

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QPX2014
Description: antibiotic
Study: NCT04507958

Intervention type: DIAGNOSTIC_TEST
Intervention: auscultation by using conventional stethoscope without PPE
Description: In thoracic patients undergoing general anesthesia with endotracheal tube/endobronchial blocker, Clinician will check the position of endotracheal tube and endobronchial blocker under fiberscope. Afterward, investigator A will perform auscultation with traditional auscultation, then investigator B with electronic stethoscope under full PPE, to examine bilateral breathing sound.

Intervention type: DIAGNOSTIC_TEST
Intervention: auscultation by using electronic stethoscope in full PPE
Description: In thoracic patients undergoing general anesthesia with endotracheal tube/endobronchial blocker, Clinician will check the position of endotracheal tube and endobronchial blocker under fiberscope. Afterward, investigator A will perform auscultation with traditional auscultation, then investigator B with electronic stethoscope under full PPE, to examine bilateral breathing sound.
Study: NCT00700011

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clofarabine
Description: 10 mg/m2 x 5 days per 4 to 6 week cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clofarabine
Description: 5 mg/m2 x 5 days per 4 to 6 week cycles
Study: NCT03419091

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: single-use flexible digital ureteroscope
Description: Device being tested.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Reusable Ureteroscope
Description: Comparative device.
Study: NCT03354494

Intervention type: DRUG
Intervention: Desogestrel (DSG) and Corifolitropin (FSH-CTP) Alfa
Study: NCT04449367

Intervention type: PROCEDURE
Intervention: ultrasound guided erector spinae plane block
Description: bilatral block given to patients under general anaesthesia for thoracic spine sugery to contorl post operative pain
Study: NCT01900613

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Ninos Sanos Familia Sana

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ninos Sanos Familia Sana
Study: NCT01067703

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Remote Ischemic Preconditioning
Description: RIPC will be induced during anesthesia by four 5-min cycles of upper limb ischemia and 5-min reperfusion using a blood-pressure cuff inflated to a pressure 200 mm Hg, whereas the pressure has to be at least 20 mm Hg greater than the systolic arterial pressure measured via the arterial line.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Control/sham procedure (blood pressure cuff)
Description: Sham placement of the blood pressure cuff around a dummy arm inflated to a pressure of 200 mm Hg with four cycles of 5 min inflation and 5 min deflation.
Study: NCT03069027

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: External nasal nerve block
Description: Three single (midline injection) and 4 paired (bilateral injection) sites to block the external nasal sensation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: External nasal nerve block
Description: Three single (midline injection) and 4 paired (bilateral injection) sites to block the external nasal sensation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline adrenaline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xylocaine, adrenaline
Study: NCT01941953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin and Fluorouracil
Description: metformin 850mg PO BID plus 5FU 425mg/m2 + leucovorin 50mg IV weekly